You are here

Novartis puts pressure on Roche with cheap copy of Rituxan

Zurich

SWITZERLAND'S Novartis increased pressure on Roche's ageing stable of big-selling drugs on Monday by becoming the latest company to win European approval for a cut-price version of Rituxan for blood cancer and immunological diseases.

Rixathon, from Novartis's Sandoz generics

sentifi.com

Market voices on:

Powered by GET.comGetCom